Infliximab

    Page 1 of 3 - About 21 Essays
  • Infliximab

    Using infliximab to treat Crohn’s disease Introduction Crohn’s disease is a type of IBD that causes inflammation in any part gastrointestinal tract from the mouth to the anus. In response to this inflammation, the body’s immune system attacks the GI tract (Dessein, 2008). The progression of this chronic inflammatory disease is brought about by the action of several cellular processes and pro-inflammatory mediators (Poggioli, 2007). Because there is no single factor that can be targeted to stop the development of Crohn’s disease, there is no cure for it. However, certain drugs can be used to target specific mediators in order to treat the disease. Infliximab is an example of a drug that is used to treat CD by targeting a proinflammatory cytokine called tumour necrosis factor-α (Colombel, 2010). Mechanism of action of Infliximab Tumour necrosis factor-α is a type II transmembrane protein that is released by active T…

    Words: 1297 - Pages: 6
  • Crohns: A Case Study

    S feels some the side effects from medications are just as bad at the symptoms of Crohns. For example Humira (adalimumab) is a class of drug called disease-modifying antirheumatic drugs (DMARDs), an immunosuppressive drugs that interfere with natural immune function to reduce the inflammation in his colon (Burchum & Rosenthal, 2016). These types of medications increase the risk of infection and cancer (Burchum & Rosenthal, 2016). After taking Methotrexate (another DMARD), S developed lungs…

    Words: 1354 - Pages: 6
  • Infliximab Case Study

    CASE STUDY3: INFLIXIMAB & ITS BIOSIMILAR Infliximab is a chimeric, anti-tumor necrosis factor monoclonal antibody which is effective in patients with active rheumatoid arthritis. Infliximab is traded under the name “remicade” and is originally licensed by Janssen. It works by binding to TNF-α and inhibits the binding of TNF-α with its receptor. TNF-α is a cytokine (chemical messenger) that is involved in systemic inflammation. CT-P13 (brand name- inflectra) is a biosimilar of infliximab…

    Words: 733 - Pages: 3
  • Infliximab Research Paper

    DISCUSSION The aim of this study is to assess the efficacy of infliximab in the treatment of ulcerative colitis and to observe the presence of any side effects to infliximab. Infliximab tends to be used as a third-line therapy in patients with moderate to severe UC or as a rescue therapy [8]. However, experts have proposed that earlier use during less severe disease states (i.e., moderate UC) could benefit many patients [9] [10] [11]. Furthermore, infliximab can potentially attain the new…

    Words: 1613 - Pages: 7
  • Prometheus Anser Ifx Testing Case Study

    Indeed, experts have noted that adjusting drug doses based on clinical symptoms is often inaccurate. Furthermore, multiple factors in addition to anti-drug antibodies may influence pharmacokinetics (e.g., gender, body size, disease severity, TNF burden, and serum albumin). Finally, maintenance of an optimal drug level is associated with improved clinical outcomes, suggesting a role for therapeutic drug monitoring in routine clinical practice. After dose optimization they demonstrated that…

    Words: 1214 - Pages: 5
  • Papers On Crohn's Disease

    Immunosuppressants like Azathioprine have been used successfully to induce and maintain remission. Azathioprine is a cytotoxic drug that interferes with both cell mediated and humoral immunity by suppressing the proliferation of B and T lymphocytes. Cytotoxic drugs are nonspecific, so they can destroy any proliferating cells. This can cause major adverse effects such as pancreatitis and neutropenia, so they are usually reserved for patients who have not responded well to other drug therapies…

    Words: 1391 - Pages: 6
  • Ulcerative Colitis Case Study

    Antibodies directed against TNF-α include infliximab (IFX), a monoclonal chimeric antibody, adalimumab (ADA) and golimumab (GLM), both humanized monoclonal antibodies. These therapy agents have been proven to be effective for obtaining and maintaining clinical remission in UC [10-12, 14, 15]. In ulcerative colitis, the benefit of the combination of anti-TNF-α agents with an IS (combination therapy) remains debated. In Crohn’s disease (CD), the SONIC trial, reported that there is superiority of…

    Words: 973 - Pages: 4
  • Research Paper On Psoriasis

    patient should be involved in decision-making from the start. The specific treatment varies according to the location, severity, clinical variants and duration of the disease. Topical agents such as vitamin D analogues, corticosteroids, tacrolimus, pimecrolimus, tazarotene, anthralin, coal tar and salicyclic acid have all demonstrated efficacy in the treatment of psoriasis. Special attention should be given to the duration and dose of topical corticosteroids due to the risk of local and…

    Words: 665 - Pages: 3
  • Causes Of Psoriasis: A Chronic, Autoimmune Disease

    digits, and deformities of the Distal interphalangeal joints of fingers and toes involved with psoriatic nail changes. Typically, skin lesions are associated with psoriasis. Sometimes proliferative synovitis of the wrists and fingers occur, resembling rheumatoid arthritis. In these cases, x-rays and laboratory testing help to differentiate the two diseases. Treatment for both conditions are similar, using anti-inflammatory agents, anti-malarials, and adding methotrexate (paul,2012). …

    Words: 593 - Pages: 3
  • Psoriasis Vulgaris Research Paper

    Important parameters required for systemic treatment: Severity of psoriasis (PASI), life quality (DLQI), presence of psoriatic arthritis, pregnancy, man attempting to conceive a child, history of hematologic malignancy, immunodeficiency, alcohol use. Baseline laboratory workup before systemic treatment include comprehensive metabolic panel, complete blood count. Additionally, β-human chorionic gonadotropin, lipid panel, hepatitis markers (hepatitis B and C) and PPD or quantiferon test should be…

    Words: 628 - Pages: 3
  • Previous
    Page 1 2 3

Related Topics:

Popular Topics: